CHGCF OTC
Chugai Pharmaceutical Co., Ltd.
1W: -7.8%
1M: -8.0%
3M: -15.9%
YTD: -27.1%
1Y: -13.9%
3Y: +30.4%
5Y: +6.2%
$38.27
+0.43 (+1.13%)
Weekly Expected Move ±14.7%
$27
$33
$38
$44
$50
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$63.0B
52W Range34.788-68.08
Volume429
Avg Volume8,094
Beta0.54
Dividend$1.34
Analyst Ratings
No analyst coverage
Company Info
CEOOsamu Okuda
Employees7,872
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Date2012-08-03
Websitechugai-pharm.co.jp
Nihonbashi Mitsui Tower
Tokyo, TY 103-8324
JP
Tokyo, TY 103-8324
JP
81 3 3281 6611
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.
Latest News
Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight
3 Japanese AI Healthcare Stocks Investors May Want To Watch
RG-6299 Sales Forecast, and Market Size Analysis - 2034 Released — Examines Mechanism, Dosing, Pricing, Patents, and Emerging Competitors
Travere Therapeutics Inc (TVTX) (Q2 2026) Earnings Call Highlights: Record FILSPARI Demand and ...
Recent Insider Trades
No insider trades found